No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Renal Cell Carcinoma
Bone-Targeted Therapies in mRCC May Improve Survival
A small study of patients with metastatic renal cell carcinoma and bone metastases found a trend toward better survival among patients treated with TKIs plus bone-targeted therapies vs those treated with TKIs alone.
Updated Recommendations Issued for Treating Advanced RCC
Axitinib plus pembrolizumab is recommended as first-line therapy for patients with favorable-risk clear cell advanced renal cell carcinoma, according to an updated position statement from the Society for Immunotherapy of Cancer.
High-Throughput Multichain Immune Repertoire Sequencing for Prediction of Treatment Response in Renal Cell Carcinoma
Next-generation sequencing is being increasingly used to characterize the diversity of T-cell and B-cell receptors in individuals.
High Vitamin D Binding Protein Levels Up RCC Risk
The highest vs lowest quartile of vitamin D binding protein was associated with 4.1-fold increased odds of renal cell carcinoma in adjusted analyses.
Microwave Ablation Feasible for cT1b Renal Cell Carcinoma
Microwave ablation for cT1b renal cell carcinoma has outcomes that compare favorably with partial and radical nephrectomy, a study found.
Machine-Based CT May Help Identify BAP1 Mutation Status in Clear Cell Renal Cell Carcinoma
The method could more accurately classify patients with clear cell disease.
Longer Duration of Steroids May Affect Outcomes During Anti-PD-1 Treatment
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery
Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.
Durable Positive Effects of First-Line Pembrolizumab in Advanced RCC Reported
Updated follow-up of patients in the KEYNOTE-427 trial showed that first-line pembrolizumab for advanced clear cell renal cell carcinoma exerts favorable antitumor activity after a median 23 months of follow-up.
Next post in Kidney Cancer
